Cadrenal Therapeutics, Inc. (CVKD)

Market Cap	13.24M
Revenue (ttm)	n/a
Net Income (ttm)	-6.24M
Shares Out	1.07M
EPS (ttm)	-5.89
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,365
Open	12.52
Previous Close	12.00
Day's Range	12.19 - 12.55
52-Week Range	5.40 - 32.55
Beta	n/a
Analysts	Strong Buy
Price Target	52.50 (+323.04%)
Earnings Date	Nov 8, 2024

About CVKD

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Po...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 20, 2023
• Employees: 4
• Stock Exchange: NASDAQ
• Ticker Symbol: CVKD
• Website: https://www.cadrenal.com

Analyst Forecast

According to 2 analysts, the average rating for CVKD stock is "Strong Buy." The 12-month stock price forecast is $52.5, which is an increase of 323.04% from the latest price.

Price Target

$52.5

(323.04% upside)

Analyst Consensus: Strong Buy